Merck & Co. Inc. stock performance has seen fluctuations over the recent times. The stock price has exhibited a strong upward trend garnering interest due to their successful cancer drug, Keytruda, and approval from FDA for their Cardiovascular Disease Drug and Winrevair. The sales of Keytruda have been reported to be more than expected, leading to a rise in Merck's stock price. The company’s stock has also reached record highs based on the strong sales of its cancer drugs and vaccines. Merck also outperformed their competitors in strong trading days and grabbed attention by being a favourite among institutional investors. However, the company has been underperforming compared to competitors on certain days. There is speculation around the stock being overpriced based on weak financial prospects. Insider activity noticed signals caution. The company also made the news with their intent to acquire Harpoon Therapeutics for $680 million and Elanco’s aqua health business for $1.3 billion.
Merck Stocks News Analytics from Tue, 14 Nov 2023 08:00:00 GMT to Fri, 10 May 2024 10:02:41 GMT -
Rating 5
- Innovation 3
- Information 8
- Rumor -6
